During Wednesday’s trading session, the shares of this micro-cap pharmaceutical company surged by around 14.2 percent to Rs. 344 on BSE, after reporting Q2 FY25 results with a rise in net profit by around 7718 percent QoQ and 69 percent YoY.
With a market cap of Rs. 527.3 crores, at 01:08 p.m., the shares of Kilitch Drugs (India) Limited were trading in the green at Rs. 327.9, up by nearly 8.8 percent, as compared to its previous closing price of Rs. 301.35.
What’s the news:
The fluctuations in the share prices were observed after Kilitch Drugs (India) Limited announced the financial results for Q2 FY25, through the latest filings with the stock exchanges on Tuesday post-market hours.
For Q2 FY25, Kilitch Drugs reported revenue from operations of Rs. 47.5 crores, reflecting a significant growth of around 41.8 percent QoQ from Rs. 33.5 crores in Q1 FY25, and increased by about 15.3 percent YoY from Rs. 41.2 crores in Q2 FY24.
The company’s net profit for Q2 FY25 grew to Rs. 8.6 crores, representing a rise of around 7718.2 percent QoQ from Rs. 0.11 crores in Q1 FY25, and a year-on-year growth of nearly 69 percent from Rs. 5.09 crores in Q2 FY24.
Shareholding Pattern:
As per the September 2024 shareholding pattern, the Promoters hold a 69.23 percent stake in the company, while the remaining 30.77 percent is held by Retail Investors in Kilitch Drugs.
Stock Performance:
The stock has delivered positive returns of nearly 3.4 percent in one year, as well as around 3 percent returns in the last six months. So far in 2024, the shares of Kilitch Drugs have given negative returns of about 8.8 percent.
About the company:
Founded in 1978, Kilitch Drugs (India) Limited is a pharmaceutical company mainly engaged in the business of development and operations of Pharmaceutical Products, and its services range from manufacturing to marketing a host of formulations in all dosage forms.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
